Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 16 → 17·18:44, 1 Jan 2025
Difference between revision 16 and revision 17 of Adverse effects of GLP-1 receptor agonists. 3 lines changed; the page grew by 353 bytes.
| Revision 16 — 21:03, 16 Dec 2024 GastroparesisGwen (talk) move a stray full stop inside the reference 4,129 bytes ±0 | Revision 17 — 18:44, 1 Jan 2025 SarcopeniaSefa (talk) ce 4,482 bytes +353 | ||
|---|---|---|---|
| 32 | Acute pancreatitis has been reported and is uncommon. Trial data have not established a causal relationship, and the background rate in populations with obesity and type 2 diabetes is itself elevated, which makes a modest excess hard to detect.{{r|nauck2016}} | 32 | Acute pancreatitis has been reported and is uncommon. Trial data have not established a causal relationship, and the background rate in populations with obesity and type 2 diabetes is itself elevated, which makes a modest excess hard to detect.{{r|nauck2016}} |
| 33 | 33 | ||
| + | 34 | The medullary thyroid carcinoma contraindication derives from rodent C-cell hyperplasia and tumours at high exposure. Rodent C cells express the receptor at much higher density than human C cells, and no human signal has been established; the contraindication is precautionary. See [[Medullary thyroid carcinoma]].{{r|drucker2018}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |
| ⋮ | ⋮ | ||
| 44 | * [[Gastric emptying]] | 46 | * [[Gastric emptying]] |
| 45 | * [[Aspiration risk under anaesthesia]] | 47 | * [[Aspiration risk under anaesthesia]] |
| + | 48 | * [[Hypoglycaemia]] | |
| 46 | 49 | ||
| 47 | {{DEFAULTSORT:Adverse effects of GLP-1 receptor agonists}} | 50 | {{DEFAULTSORT:Adverse effects of GLP-1 receptor agonists}} |